UH Seidman Cancer Center at ASCO 2026

Physicians, researchers and trainees from University Hospitals Seidman Cancer Center are presenting their latest research at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world’s leading forums for oncology innovation and discovery.

This page highlights posters and presentations led by UH faculty and collaborators across a range of cancer specialties, reflecting ongoing efforts to advance cancer care through clinical research, translational science, and multidisciplinary collaboration. Explore the list below to see the breadth of work being shared on a national stage.

Jorge Garcia, MD

Speaking and representing UH Seidman Cancer Center on behalf of Theodoros Teknos, MD

Premier Applied Sciences |  Premier Inc.

• The Next Oncology Arms Race: Data, Evidence, and the Future of Cancer Innovation
• Cancer Innovation Is Accelerating — Can Evidence Keep Up?
• The End of Evidence Silos: Why Oncology’s Future Runs on Real-World Data

• Moderator ASCO Radiopharmaceutical Therapy in Oncology: Practical Integration for Practicing Oncologists | June 1, 2026 4:30 - 6:00 p.m. | Room E253cd


• Poster Session: Genitourinary Cancer—Prostate, Testicular, and Penile | May 31, 2026
• [Abstract: 5082] Independent validation of a model to predict early favorable PSA response (NADIR model) in enzalutamide-treated patients of the ARCHES trial

Alberto Montero, MD

• Poster Session - Breast Cancer—Metastatic | June 1, 2026
• [Abstract: 1122] AI-driven H&E plasma cell to predict pathological complete response in IO-treated triple-negative breast cancer (Yale; NCT02489448)

Amit Mahipal, MPH, MBBS

• Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | May 30, 2026
• [Abstract 4163] Comparative outcomes of first-line atezolizumab plus bevacizumab (A+B) and durvalumab plus tremelimumab (D+T) in hepatocellular carcinoma (HCC)
• [Abstract: 4109] Real-world treatment patterns and clinical outcomes among cholangiocarcinoma patients treated with futibatinib or pemigatinib

Sarina Ailawadi, DO (Presenter) | Amit Mahipal, MPH, MBBS (Senior Author)

• Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
• [Abstract: e16426] Comparative clinical outcomes with lenvatinib versus cabozantinib post-progression on first-line immunotherapy in patients with advanced hepatocellular carcinoma.

Wesley Dean Boland, MD

• [Abstract: e15696] Metabolic comorbidity burden and oncologic features of early onset colorectal cancer stratified by hepatic steatosis

Emanuela Ferraro

• Poster Session - Central Nervous System Tumors [Poster Board: 396]
• [Abstract: 2031] Intracranial Pharmacokinetics and Resistance Mechanisms of Tucatinib In Patients with HER2+/mutant solid tumors and brain metastasis: Results from the WinHER2 study (NCT05892068)

Jeffry Zhong, MD (Presenter) | Jason Brown, MD, PhD (Senior Author)

• [Abstract: 4565] Effect of on-treatment dose adjustments on the efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.

Rishi Patel, MD (Presenter) | Jason Brown, MD, PhD (Senior Author)

• [Abstract: 4584] Risk and patterns of recurrence for patients (pts) with advanced urothelial carcinoma (aUC) metastatic to liver after response to enfortumab vedotin + pembrolizumab (EVP).
• Selected for the ASCO Leadership Development Program - Education Scholars

Soumyajit Roy, MD, MPH, MBBS (Presenter) | Jason Brown, MD, PhD (Co-Author)

• [Abstract: 5082] Independent validation of a model to predict early favorable PSA response (NADIR model) in enzalutamide-treated patients of the ARCHES trial

Qiuchen Li, BA (Presenter) | Lauren Chiec, MD (Senior Author)

• Poster Session: Quality Care/Health Services Research Session [Poster Board: 126]
• [Abstract: 11143] Clinical associations of cannabis use among patients receiving immune checkpoint-inhibitors: A real-world analysis

• Co-Chair of Symptom Science and Palliative Care, rapid oral abstract session | May 31, 2026 8:00 - 9:30 a.m.

Madison Conces, MD

• Poster Session - Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary [Poster Board 231b]
• [Abstract: TPS4258] A phase II trial of trifluridine/tipiracil plus oxaliplatin in patients with advanced or metastatic biliary tract cancer following first-line therapy


• Poster Session - Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology [Poster Board 172]
• [Abstract: 3035] BC3195, a novel ADC targeting cadherin-3 (CDH3): Preliminary results of a phase I study in patients with advanced solid malignancies (study BC3195-102)

Mindy Hsu, MD

• [Abstract: 8111] An innovative team approach to improve SCLC care across an integrated health system

• Invited speaker at ASCO Manta Cares Event | May 29, 2026

Pedro Barata, MD

• Oral Presentation: [Abstract: LBA5009] Safety and dosimetry of 177Lu-rosopatamab tetraxetan plus SoC in patients with metastatic castration-resistant prostate cancer: Preliminary results from part 1 of phase 3 ProstACT Global Study | June 1, 2026

Timothy O'Brien, MD

• Rapid Oral Abstract Presenter | May 31, 2026 | 9:57 - 10:03 a.m. | Room E450a 
• [Abstract 7511] Survival outcomes comparing sequencing of CAR-T followed by BiTE versus BiTE followed by CAR-T in patients with relapsed multiple myeloma.

• Poster Session: Hematologic Malignancies - Plasma Cell Dyscrasia
• [Abstract 7573]: Early intravenous immunoglobulin use in multiple myeloma patients treated with talquetamab: Effect on risk of infections and mortality
• Poster Session: Hematologic Malignancies - Plasma Cell Dyscrasia | June 1, 2026
• [Abstract: 7575] Plasma exchange in Myeloma-Associated Acute Kidney Injury: A Multicenter Propensity-Matched Cohort Study